Condition: Follicular Lymphoma · Sponsor: Institute of Hematology & Blood Diseases Hospital, China
This study is planned to prospectively evaluates the efficacy and safety of the zanubrutinib, obinutuzumab, and lenalidomide (ZGR) combination regimen in treatment-naïve follicular lymphoma (FL) patients in a Chinese population.
This description comes directly from the study's public registry record.
Shuhua Yi, Dr · +86-022-23909106 · yishuhua@ihcams.ac.cn
Rui Lyu · +86-022-23909106 · lvrui@ihcams.ac.cn
Always discuss trial participation with your own doctor first.
| Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences, Tianjin, Tianjin 300020 | Tianjin, Tianjin Municipality, China | Not Yet Recruiting |
| Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07299149